Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 25, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2025

Conditions
Subarachnoid Hemorrhage, AneurysmalDelayed Cerebral IschemiaVasospasm, Cerebral
Interventions
DRUG

Nimodipine

If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.

Trial Locations (1)

1090

RECRUITING

Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

University of Vienna

OTHER

collaborator

Austrian Science Fund (FWF)

OTHER

lead

Medical University of Vienna

OTHER